Fishers, Ind. – Executives from California-based 1Elevan Biopharmaceuticals, a peptide therapeutics pharmaceutical company, announced today its plans to relocate and begin a $7 million renovation for its new headquarters in the Fishers Life Sciences and Innovation Park at 12001 Exit 5 Parkway in Fishers, Indiana.
Darrin Carrico, President and CEO of 1Elevan Bio, said, “1Elevan Bio chose Fishers, Indiana, because the city is dedicated to supporting biotechnology. Fishers has become an epicenter for biopharmaceutical innovation, manufacturing, and distribution, attracting established industry leaders.” He added, “Simply stated, it is a rare confluence of biotech companies involved in impactful science, intentionally collaborative, empowering unfettered innovation.”
The 133,500-square-foot space will feature a pharmacy licensed for category III, 503A/503B compounding, as well as on-site telemedicine providers for peptide therapy management and prescription services. The company will phase in peptide manufacturing, new drug development, and contract development and manufacturing (CDMO). 1Elevan Bio will create 120 new jobs in Indiana over the next five years, offering a full continuum of peptide therapeutics and services as they become available, with satellite operating sites in California and Florida to support a national footprint.
“Fishers has established itself as a hub for innovation in life sciences globally,” said Fishers Mayor Scott Fadness. “Today’s news from 1Elevan shows another example of how our efforts to bring innovative companies and workforce to our community have become a reality. We look forward to seeing the impact 1Elevan will have on its industry in the coming years.”
Founded in 2022 in California with intentions of building operations in San Diego’s biotech community, 1Elevan Bio’s move to Indiana is the result of the state’s business-friendly environment and Fishers’ burgeoning biotech industry. The move has been a homecoming for members of the executive team, which comprises several graduates of Purdue University. The proximity to the leading university offers opportunities to partner with their alma mater for new innovations.
1Elevan Bio expects to conclude renovations this summer with operations launching in September 2025.
###
About the Fishers Life Sciences and Innovation Park
Developed by the City of Fishers in 2021, the Fishers Life Sciences and Innovation Park is the hub of the city’s global life science industry. With over 70 acres, the Park is home to multiple life science-related firms, from supplier materials to research and development to CDMOs. For more information, visit econdev.fishersin.gov.
About 1Elevan Biopharmaceuticals
Founded in 2022, 1Elevan Bio is dedicated to advancing peptide therapeutics to improve human health and expand patient access to effective treatments. The company delivers FDA-approved and FDA-expanded-access pharmaceutical peptides aimed at treating chronic diseases in adjunctive, first-line, or potentially curative roles. By leveraging the body’s natural pathways, 1Elevan Bio is at the forefront of a shift away from costly, traditional small-molecule drugs with uncertain outcomes—ushering in a new beginning of pharmacological medicine rooted in science, empowerment, and innovation. Learn more at https://1elevan.com
